Company Overview of Innovacell Biotechnologie AG
Innovacell Biotechnologie AG develops personalized cell therapies for treatment of incontinence. It provides ICES13 and ICEF15, cell-based therapy products for treatment of stress urinary incontinence and faecal incontinence, respectively. The company was founded in 2000 and is based in Innsbruck, Austria. It has laboratory and productions facilities in Innsbruck, Austria.
Life Science Center
Founded in 2000
43 512 - 573680
43 512 - 573680-5
Key Executives for Innovacell Biotechnologie AG
Innovacell Biotechnologie AG Key Developments
Similar Private Companies By Industry
|Activartis Biotech GmbH||Europe|
|APEIRON Biologics AG||Europe|
|Apeptico Forschung und Entwicklung GmbH||Europe|
|ARTMA Medical Technologies AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Innovacell Biotechnologie AG, please visit www.innovacell.at. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.